ASX BRIEFS

Send us Fan Mail

Ignacio Salazar, the dynamic CEO and Managing Director of Highfield Resources, joins us in an episode bubbling with excitement and opportunity. Ever wondered what it takes to transform a company into a global contender? Ignacio shares how Highfield Resources is stepping up its game with groundbreaking developments at the Muga potash project in Spain and an ambitious leap into the Canadian market. You'll uncover the backstory of securing vital investments that not only fully fund Muga's construction but also bring new assets into play, setting the stage for Highfield's ascent in the potash industry.

Ignacio opens up about the strategic alliance with Yankuang Energy and the acquisition of the Southey Potash project, revealing how these moves align with Highfield's vision of global leadership in the potash sector. With assets spanning Europe and North America, Highfield Resources is poised to compete on a worldwide scale. Tune in to discover the synergies between their Spanish and Canadian projects and learn how experience and foresight are propelling them to new heights. From funding breakthroughs to future roadmaps, this conversation is packed with insights for anyone eyeing the global potash market.

Send us Fan Mail

Unlock the secrets of clean energy innovation with Neil McDonald, Managing Director of Gold Hydrogen Limited, as he joins us to discuss the company’s groundbreaking journey in South Australia's York Peninsula. With helium purity levels reaching an unprecedented 36.9%, Gold Hydrogen is not just making discoveries; they're setting new standards in natural hydrogen and helium exploration. Get ready to explore how these extraordinary results position the company as a leader in clean energy solutions at a time when global demand has never been higher.

Neil walks us through the strategic steps Gold Hydrogen is taking to transition the Ramsey project from exploration to commercial success. Discover their cutting-edge plans for drilling and resource optimization, and hear about their exciting collaboration with Mizuho, a Japanese banking giant, which could accelerate their entry into international markets. With Japan's strong commitment to a hydrogen economy, this partnership could be a game-changer. Tune in to understand how Gold Hydrogen is poised to revolutionize the energy sector and what their advancements mean for the future of sustainable energy.

Send us Fan Mail

What if the shift from lithium to copper exploration could redefine the future of a resource company? Glenn Poole, CEO and MD of Firetail Resources Limited, joins us to peel back the layers of this strategic transition. As Firetail pivots its focus to copper across Canada, Peru, and Australia, Glenn reveals the exciting opportunities and challenges that lie ahead. From the recent land expansion at the Skyline Copper Project in Canada to the exploration of overlooked sulfide zones, listeners will gain a comprehensive understanding of the company's next steps and the potential growth in untapped areas.

Join us as Glenn takes us through Firetail's ambitions to unlock a larger mineralized system with a holistic approach and strategic drilling campaigns. Discover how Firetail plans to capitalize on its contiguous land package and what the Helii EM survey could mean for their exploration timeline. Glenn also shares key milestones and future opportunities that could significantly impact Firetail's trajectory and offer new prospects for investors. This episode is packed with insights that highlight Firetail's commitment to innovation and strategic growth in the copper exploration landscape.

Send us Fan Mail

Get ready to explore the cutting-edge world of cancer treatment with Dr. Chris Burns, CEO & MD of Amplia Therapeutics Limited and co-recipient of the 2024 Prime Minister's Prize for Innovation. Our latest episode of ASX Briefs takes you inside Amplia's groundbreaking work with Focal Adhesion Kinase (FAK) inhibitors, specifically their promising small molecule inhibitor, designed to tackle pancreatic cancer head-on. Dr. Burns shares the significant milestones in their ACCENT trial, including the recruitment of the first 26 patients and the remarkable achievement of six confirmed partial responses, which may signal a new frontier in cancer therapy.

Join us as Dr. Burns uncovers the science behind Amplia's innovative approach and how their treatment aims to enhance the effectiveness of existing therapies. He discusses the trial's progress, the potential for improved patient outcomes, and the exciting path forward with further recruitment underway. This episode is a compelling listen for anyone passionate about the future of oncology and the relentless pursuit of breakthroughs in cancer treatment. Don't miss the chance to hear firsthand from a leader at the forefront of medical innovation.

Send us Fan Mail

What if a single strategic move could redefine the music and media industries? Join us on ASX Briefs as we uncover the secret sauce behind Vinyl Group Limited's trailblazing success with their CEO, Josh Simons. Josh returns to share how the company, which boasts the world's only official music credit database, is pushing boundaries with innovative strategies and smart acquisitions. Discover the seamless integration of platforms like Jaxsta and Vampr, and learn how their revamped interfaces promise an even more dynamic user experience. Explore how their acquisition spree, including Jaxsta, Vampr, and Media Week, is positioning Vinyl Group at the forefront of the creator economy and media landscape.

But that's not all—Josh delves into Vinyl Group's strategic expansion into the realm of collectibles with the London-based Web3 pioneer, Serenade. This move aligns with their ambitious Vinylcom initiative and is set to boost cash flow significantly. Hear firsthand about the impact of acquiring Funkified Entertainment and how bringing event management in-house is a game-changer for improving margins. As the company targets a break-even point by FY26, Josh shares insights on the art of identifying promising acquisition targets that fuel growth. Don't miss out as we explore how Vinyl Group is reshaping the future of music and media with visionary leadership and strategic foresight!

Send us Fan Mail

Explore the transformative journey of Percheron Therapeutics with Dr. James Garner at the helm, as he shares the company's pioneering efforts in the field of rare disease therapies. Discover how their strategic evolution from Antisense Therapeutics to Percheron Therapeutics has positioned them at the forefront of developing groundbreaking treatments for Duchenne muscular dystrophy (DMD). As we delve into the intricacies of their phase 2b trial of avicursen for non-ambulant boys, Dr. Garner reveals the innovative use of the Performance in the Upper Limb (PUL2.0) endpoint and the promising results from their essential non-human primate toxicology study, aligning with FDA requirements for future clinical trials.

Uncover the strategic blueprint Percheron employs to bring their therapies to market, leveraging Ionis Pharmaceuticals expertise and carefully outsourcing critical tasks, allowing them to concentrate on clinical development. Dr. Garner outlines their ambitious commercialization plans, aiming to partner with larger entities for broader market reach. With pivotal data readouts expected soon and ongoing conversations with the FDA, Percheron is on a mission to de-risk their drugs and attract strong partners. Listen in to understand how these innovative therapies could significantly impact the lives of patients with rare diseases, paving the way for a brighter future.

Send us Fan Mail

Unlock the secrets of the helium supply chain with Shaun Scott, the dynamic Managing Director and CEO of Noble Helium. Discover how the company is setting a new course in helium exploration with cutting-edge projects in Tanzania. Shaun shines a light on a staggering 67% boost in the P50 helium prospective resource at the North Rukwa Basin, sharing the innovative strategies that made this achievement possible. As we venture into the prospects on the eastern side of the basin, Shaun reveals Noble Helium's strategic plans to navigate the challenges of deep exploration and the potential partnerships on the horizon.

Get an insider's perspective on the pivotal role of helium in powering high-tech industries and the nuanced geopolitical factors reshaping its global supply chain. Shaun discusses the advantages of primary helium production over byproduct extraction and outlines Noble Helium's vision for the next 12 to 18 months. From shallow drilling revelations to the quest for farm-in partners for deeper targets, this episode is packed with critical insights and future-focused strategies that underscore helium's vital importance in our technological future.

Send us Fan Mail

Discover the strategic insights of Ed Ainscough, Managing Director of Lunnon Metals Limited, as he reveals the company's bold transition from nickel to gold exploration amidst challenging market conditions. With a storied history in the Kambalda Nickel District, Lunnon Metals has strategically pivoted to capitalize on their promising gold assets, particularly at the Lady Herial Prospect. Ed shares how this shift was not only a response to external challenges but also a calculated move to leverage the soaring gold prices, ensuring value creation for shareholders while maintaining a strong cash position.

Join us as Ed uncovers the impressive recent findings at the Lady Herial Prospect and discusses the exciting opportunities they present for Lunnon Metals. Learn how the company's reassessment of its gold portfolio, backed by a solid legacy and strategic foresight, positions it to navigate the evolving commodity landscape. This episode is a must-listen for anyone interested in the mining and exploration sector, offering a deep dive into how strategic decisions can drive growth and resilience in a volatile market.

Send us Fan Mail

What if turning trash into treasure could be the key to decarbonizing entire nations? Join us for an insightful conversation with Joe Oliver, the visionary CEO of Delorean Corporation, as he shares his compelling journey in the bioenergy sector. Discover how Delorean is pioneering advancements in organic waste conversion, positioning themselves at the forefront of renewable energy solutions in Australia and New Zealand. Joe reveals the details behind Delorean's recent $30 million funding success for the ambitious SA1 project and how this strategic move is transforming their operational model to build-own-operate, setting the stage for impressive growth and infrastructure ownership.

In our latest episode, Joe offers a glimpse into the dynamic future of Delorean with updates on the VIC-1 project, aligning with the company's long-term vision of green gas production. As we explore the robust project pipeline and strong financial performance in FY 2024, you'll gain valuable insights into Delorean's role in reducing emissions and supporting third-party clients. This conversation is not just about numbers but about the vital steps being taken to reshape the renewable energy landscape, showcasing Delorean's commitment to sustainability and innovation. Tune in to understand the transformative strides this leader in the bioenergy market is making and what it means for the future of renewable energy.

Send us Fan Mail

What if controlling a single hormone in your brain could revolutionize the treatment of Alzheimer's and depression? On this episode of ASX Briefs, we're joined by Steve Gourlay, CEO of Actinogen Medical, a trailblazer in biotechnology, to unveil how their groundbreaking drug, Xanamem, could be a game-changer for mental health therapies. Steve takes us through Actinogen's fascinating journey from their 2014 merger with a University of Edinburgh startup to the promising Phase 2 depression trial results, where 167 patients showed significant improvement with minimal side effects.

Steve demystifies the complex science behind Xanamem, explaining how it targets brain cortisol, a hormone infamous for its role in stress and cognitive decline. With a deep dive into the biology of the brain, Steve enlightens us on how selectively reducing cortisol in regions like the hippocampus and frontal cortex can prevent the detrimental effects of chronic stress on nerve cells. This episode is a must-listen for anyone interested in the future of mental health treatment and how innovative therapies are set to change the landscape.